Poltreg (WAR:PTG) Other Financing: zł-0.72 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:PTG Poltreg SA WAR:PTG
42 GF Score
Price zł19.40
GF Value zł14.20
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Poltreg Other Financing?

Poltreg WAR:PTG +2.11% 42 Other Financing is zł-0.72 Mil as of Mar. 2026. GuruFocus rates WAR:PTG with a GF Score™ of 42/100 and a GF Value™ of zł14.20 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Poltreg's Other Financing for the three months ended in Mar. 2026 was zł-0.13 Mil.

Poltreg's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.72 Mil.

Poltreg Other Financing Historical Data

* Premium members only.

The historical data trend for Poltreg's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poltreg Other Financing Chart

Poltreg Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -0.04 2.46 20.99 4.90 1.05

Poltreg Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.20 -0.18 -0.21 -0.13
WAR:PTG
42GF Score
Poltreg SA WAR:PTG
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poltreg Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of zł-0.72 Mil mean?
Poltreg (WAR:PTG) has a Other Financing of zł-0.72 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Poltreg and its competitors.
Is Poltreg's Other Financing too high?
Poltreg's current Other Financing is zł-0.72 Mil. Overall, Poltreg has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Poltreg's Other Financing compare to VRTX and REGN?
Poltreg's Other Financing of zł-0.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Poltreg and its competitors. Poltreg's current Other Financing is zł-0.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poltreg stock overvalued right now?
Based on GuruFocus' analysis, Poltreg (WAR:PTG) is currently considered Significantly Overvalued. The stock's GF Value™ is zł14.20, compared to a current price of zł19.40 — trading 36.6% above its estimated fair value. The current Other Financing is zł-0.72 Mil. Poltreg's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Poltreg (WAR:PTG), the current Other Financing is zł-0.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poltreg (WAR:PTG) Overvalued in 2026?

Based on GuruFocus' analysis, Poltreg stock appears to be overvalued. The current stock price of zł19.40 is trading 36.6% above its estimated GF Value™ of zł14.20. GuruFocus considers Poltreg to be Significantly Overvalued.

Key valuation signals for WAR:PTG:

  • Other Financing: zł-0.72 Mil
  • GF Value™: zł14.20 vs. price of zł19.40 (36.6% above fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the WAR:PTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poltreg Business Description

Address ul.Botaniczna 20, Gdansk, POL, 80-298
Poltreg SA is a biotechnology company at the clinical stage developing an innovative generation of medicines using T-regulatory cells (TREGS) in the treatment of autoimmune diseases.
42GF Score

Get the complete analysis for WAR:PTG

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.40
Price
zł14.20
GF Value